According to GlobalData’s medical device pipeline database, 23 Soft Tissue Biologics devices are in various stages of development globally. GlobalData’s report Soft Tissue Biologics provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 13 are in active development, while the remaining 11 are in an inactive stage of development. There are nine products in the early stages of development, and the remaining four are in the late stages of development.
Soft Tissue Biologics are used in surgical procedures to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. This model focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles tendon. Other indications include medial collateral ligament (MCL), lateral collateral ligament (LCL), medial patellofemoral ligament (MPFL), ulnar collateral ligament (UCL), flexor tendon, and hip flexor repair. Soft Tissue Biologics can be either tendon grafts/reinforcements or tendon wrapping products.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Soft Tissue Biologics pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Soft Tissue Biologics devices. Overall, most of these Soft Tissue Biologics pipeline devices are being developed by private entities.
Key players involved in the active development of Soft Tissue Biologics include Colorado Therapeutics, Shandong Junxiu Biotechnology, Anika Therapeutics, BioGend Therapeutics, Acuitive Technologies, STEL Technologies, Tissue Regenix Group, University of Arizona, University of Bielefeld and University of Minnesota.
For a complete picture of the developmental pipeline for Soft Tissue Biologics devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.